Many synthetic selective estrogen receptor modulators (SERMs) have been cocrystallized with the human estrogen receptor α ligand binding domain (ERα LBD). Despite stabilizing the same canonical inactive conformation of the LBD, most SERMs display different ligand-dependent pharmacological profiles. We show here that increased partial agonism of SERMs is associated with increased conformational stability of the SERM-LBD complexes, by investigation of dihydrobenzoxathiin-based SERMs using molecular modelling techniques. Analyses of tamoxifen (TAM) and 4-hydroxytamoxifen (OHT) in complex with the LBD furthermore indicates that the conversion of TAM to OHT increases both the affinity to ERα and the partial agonism of the anti-cancer drug, which provides a plausible explanation of the counterintuitive results of TAM therapy.
Riggs, B.L. and Hartmann, L.C. (2003) Drug therapy: Selective estrogen-receptor modulators—Mechanisms of action and application to clinical practice. New England Journal of Medicine, 348, 618-629. doi:10.1056/NEJMra022219
Clarke, M., Collins, R., Davies, C., Godwin, J., Gray, R., Peto, R. and Grp, E.B.C.T.C. (1998) Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, 351, 1451-1467. doi:10.1016/S0140-6736(97)11423-4
Jordan, V.C. (2003) A most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2, 205-213. doi:10.1038/nrd1031
Sato, M., Rippy, M.K. and Bryant, H.U. (1996) Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB Journal, 10, 905-912.
Assikis, V.J., Neven, P., Jordan, V.C. and Vergote, I. (1996) A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. European Journal of Cancer, 32A, 1464-1476. doi:10.1016/0959-8049(96)00184-0
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., Skaar, T., Storniolo, A.M., Li, L., Araba, A., Blanchard, R., Nguyen, A., Ullmer, L., Hayden, J., Lemler, S., Weinshilboum, R.M., Rae, J.M., Hayes, D.F. and Flockhart, D.A. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. Journal of the National Cancer Institute, 97, 30-39. doi:10.1093/jnci/dji005
Desta, Z., Ward, B.A., Soukhova, N.V. and Flockhart, D.A. (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. Journal of Pharmacology and Experimental Therapeutics, 310, 1062-1075. doi:10.1124/jpet.104.065607
Seth, P., Lunetta, K.L., Bell, D.W., Gray, H., Nasser, S.M., Rhei, E., Kaelin, C.M., Iglehart, D.J., Marks, J.R., Garber, J.E., Haber, D.A. and Polyak, K. (2000) Phenol sulfotransferases: Hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Research, 60, 6859-6863.
Falany, C.N., Wheeler, J., Oh, T.S. and Falany, J.L. (1994) Steroid sulfation by expressed human cytosolic sulfotransferases. Journal of Steroid Biochemistry and Molecular Biology, 48, 369-375. doi:10.1016/0960-0760(94)90077-9
Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A. and Greene, G.L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95, 927-937. doi:10.1016/S0092-8674(00)81717-1
Fabian, C., Tilzer, L. and Sternson, L. (1981) Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen-receptors isolated from human-breast carcinoma—Correlation with blood- levels in patients with metastatic breast-cancer. Biopharmaceutics & Drug Disposition, 2, 381-390. doi:10.1002/bdd.2510020407
Johnson, M.D., Zuo, H., Lee, K.H., Trebley, J.P., Rae, J.M., Weatherman, R.V., Desta, Z., Flockhart, D.A. and Skaar, T.C. (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Research and Treatment, 85, 151-159. doi:10.1023/B:BREA.0000025406.31193.e8
Coezy, E., Borgna, J.L. and Rochefort, H. (1982) Tamoxifen and metabolites in Mcf7 cells—Correlation between binding to estrogen-receptor and inhibition of cell-growth. Cancer Research, 42, 317-323.
Goetz, M.P., Rae, J.M., Suman, V.J., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L., Flockhart, D.A., Desta, Z., Perez, E.A. and Ingle, J.N. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. Journal of Clinical Oncology, 23, 9312-9318. doi:10.1200/JCO.2005.03.3266
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U.M., Simon, W., Eichelbaum, M. and Brauch, H. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. Journal of Clinical Oncology, 25, 5187-5193. doi:10.1200/JCO.2007.12.2705
Goetz, M.P., Knox, S.K., Suman, V.J., Rae, J.M., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L., Weinshilboum, R.M., Fritcher, E.G.B., Nibbe, A.M., Desta, Z., Nguyen, A., Flockhart, D.A., Perez, E.A. and Ingle, J.N. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Research and Treatment, 101, 113-121. doi:10.1007/s10549-006-9428-0
Kiyotani, K., Mushiroda, T., Sasa, M., Bando, Y., Sumitomo, I., Hosono, N., Kubo, M., Nakamura, Y. and Zembutsu, H. (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Science, 99, 995-999. doi:10.1111/j.1349-7006.2008.00780.x
Xu, Y., Sun, Y., Yao, L., Shi, L., Wu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., He, L., Li, P. and Xie, Y. (2008) Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Annals of Oncology, 19, 1423-1429. doi:10.1093/annonc/mdn155
Newman, W.G., Hadfield, K.D., Latif, A., Roberts, S.A., Shenton, A., McHague, C., Lalloo, F., Howell, S. and Evans, D.G. (2008) Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clinical Cancer Research, 14, 5913-5918. doi:10.1158/1078-0432.CCR-07-5235
Nowell, S.A., Ahn, J.Y., Rae, J.M., Scheys, J.O., Trovato, A., Sweeney, C., MacLeod, S.L., Kadlubar, F.F. and Ambrosone, C.B. (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Research and Treatment, 91, 249-258. doi:10.1007/s10549-004-7751-x
Okishiro, M., Taguchi, T., Kim, S.J., Shimazu, K., Tamaki, Y. and Noguchi, S. (2009) Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer, 115, 952-961. doi:10.1002/cncr.24111
Nowell, S., Sweeney, C., Winters, M., Stone, A., Lang, N. P., Hutchins, L.F., Kadlubar, F.F. and Ambrosone, C.B. (2002) Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. Journal of the National Cancer Institute, 94, 1635-1640.
Wegman, P., Vainikka, L., Stal, O., Nordenskjold, B., Skoog, L., Rutqvist, L.E. and Wingren, S. (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Research, 7, R284-R290. doi:10.1186/bcr993
Wegman, P., Elingarami, S., Carstensen, J., Stal, O., Nordenskjold, B. and Wingren, S. (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Research, 9, R7. doi:10.1186/bcr1640
Osborne, C.K., Coronado, E., Allred, D.C., Wiebe, V. and Degregorio, M. (1991) Acquired tamoxifen resistance—Correlation with reduced breast-tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. Journal of the National Cancer Institute, 83, 1477-1482. doi:10.1093/jnci/83.20.1477
Osborne, C.K., Wiebe, V.J., Mcguire, WL., Ciocca, D.R. and Degregorio, M.W. (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast-cancer patients. Journal of Clinical Oncology, 10, 304-310.
Hermkens, P.H., Kamp, S., Lusher, S. and Veeneman, G.H. (2006) Non-steroidal steroid receptor modulators. IDrugs, 9, 488-494.
Grese, T.A., Sluka, J.P., Bryant, H.U., Cullinan, G.J., Glasebrook, A.L., Jones, C.D., Matsumoto, K., Palkowitz, A.D., Sato, M., Termine, J.D., Winter, M.A., Yang, N.N. and Dodge, J.A. (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proceedings of the National Academy of Sciences of the United States of America, 94, 14105-14110. doi:10.1073/pnas.94.25.14105
Liu, H., Park, W.C., Bentrem, D.J., McKian, K.P., De los Reyes, A., Loweth, J.A., Schafer, J.M., Zapf, J.W. and Jordan, V.C. (2002) Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. Journal of Biological Chemistry, 277, 9189-9198. doi:10.1074/jbc.M108335200
DeMichele, A., Troxel, A.B., Berlin, J. A., Weber, A.L., Bunin, G.R., Turzo, E., Schinnar, R., Burgh, D., Berlin, M., Rubin, S.C., Rebbeck, T.R. and Strom, B.L. (2008) Impact of raloxifene or tamoxifen use on endometrial cancer risk: A population-based case-control study. Journal of Clinical Oncology, 26, 4151-4159. doi:10.1200/JCO.2007.14.0921
Brzozowski, A.M., Pike, A.C., Dauter, Z., Hubbard, R.E., Bonn, T., Engstrom, O., Ohman, L., Greene, G.L., Gustafsson, J.A. and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389, 753-758. doi:10.1038/39645
Heldring, N., Pawson, T., McDonnell, D., Treuter, E., Gustafsson, J.A. and Pike, A.C. (2007) Structural insights into corepressor recognition by antagonist-bound estrogen receptors. Jounal of Biological Chemistry, 282, 10449-10455. doi:10.1074/jbc.M611424200
Kong, E.H., Heldring, N., Gustafsson, J.A., Treuter, E., Hubbard, R.E. and Pike, A.C. (2005) Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 102, 3593-3598. doi:10.1073/pnas.0407189102
Blizzard, T.A., DiNinno, F., Morgan, J.D., Chen, H.Y., Wu, J.Y., Kim, S., Chan, W., Birzin, E.T., Yang, Y.T., Pai, L.Y., Fitzgerald, P.M.D., Sharma, N., Li, Y., Zhang, Z.P., Hayes, E.C., DaSilva, C.A., Tang, W., Rohrer, S.P., Schaeffer, J.M. and Hammond, M.L. (2005) Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers. Bioorganic & Medicinal Chemistry Letters, 15, 107-113. doi:10.1016/j.bmcl.2004.10.036
Molecular Operating Enviroment (2010). Chemical Computing Group, Montreal, Canada.
Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W. and Klein, M.L. (1983) Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics, 79, 926-935. doi:10.1063/1.445869
Krieger, E., Darden, T., Nabuurs, S.B., Finkelstein, A. and Vriend, G. (2004) Making optimal use of empirical energy functions: Force-field parameterization in crystal space. Proteins-Structure Function and Bioinformatics, 57, 678-683. doi:10.1002/prot.20251
Duan, Y., Wu, C., Chowdhury, S., Lee, M.C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, R., Lee, T., Caldwell, J., Wang, J. and Kollman, P. (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. Journal of Computational Chemistry, 24, 1999-2012. doi:10.1002/jcc.10349
Wang, J., Wolf, R.M., Caldwell, J.W., Kollman, P.A. and Case, D.A. (2004) Development and testing of a general amber force field. Journal of Computational Chemistry, 25, 1157-1174. doi:10.1002/jcc.20035
Jakalian, A., Jack, D.B. and Bayly, C.I. (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. Journal of Computational Chemistry, 23, 1623-1641. doi:10.1002/jcc.10128
Krieger, E., Nielsen, J.E., Spronk, C.A. and Vriend, G. (2006) Fast empirical pKa prediction by Ewald summation. Jounal of Molecular Graphics & Modelling, 25, 481-486. doi:10.1016/j.jmgm.2006.02.009
Blizzard, T.A., Morgan, J.D., Chan, W.D., Birzin, E.T., Pai, L.Y., Hayes, E.C., DaSilva, C.A., Mosley, R.T., Yang, Y.T., Rohrer, S.P., DiNinno, F. and Hammond, M.L. (2005) Estrogen receptor ligands. Part 14: Application of novel antagonist side chains to existing platforms. Bioorganic & Medicinal Chemistry Letters, 15, 5124-5128. doi:10.1016/j.bmcl.2005.08.084
Blizzard, T.A., DiNinno, F., Chen, H.Y., Kim, S., Wu, J.Y., Chan, W.D., Birzin, E.T., Yang, Y.T., Pal, L.Y., Hayes, E.C., DaSilva, C.A., Rohrer, S.P., Schaeffer, J.M. and Hammond, M.L. (2005) Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain. Bioorganic & Medicinal Chemistry Letters, 15, 3912-3916. doi:10.1016/j.bmcl.2005.05.089
Liu, J., Birzin, E.T., Chan, W.D., Yang, Y.T., Pai, L.Y., DaSilva, C., Hayes, E.C., Mosley, R.T., DiNinno, F., Rohrer, S.P., Schaeffer, J.M. and Hammond, M.L. (2005) Estrogen receptor ligands. Part 11: Synthesis and activity of isochromans and isothiochromans. Bioorganic & Medicinal Chemistry Letters, 15, 715-718. doi:10.1016/j.bmcl.2004.11.018
Blizzard, T.A., DiNinno, F., Morgan, J.D., Chen, H.Y., Wu, J.Y., Gude, C., Kim, S., Chan, W.D., Birzin, E.T., Yang, Y.T., Pai, L.Y., Zhang, Z.P., Hayes, E.C., DaSilva, C.A., Tang, W., Rohrer, S.P., Schaeffer, J.M. and Hammond, M.L. (2004) Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains. Bioorganic & Medicinal Chemistry Letters, 14, 3861-3864. doi:10.1016/j.bmcl.2004.05.074
Blizzard, T.A., DiNinno, F., Morgan, J.D., Wu, J.Y., Chen, H.Y., Kim, S., Chan, W.D., Birzin, E.T., Yang, Y.T., Pai, L.Y., Zhang, Z.P., Hayes, E.C., DaSilva, C.A., Tang, W., Rohrer, S.P., Schaeffer, J.M. and Hammond, M.L. (2004) Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains. Bioorganic & Medicinal Chemistry Letters, 14, 3865-3868. doi:10.1016/j.bmcl.2004.05.073
Tan, Q., Birzin, E.T., Chan, W., Yang, Y.T., Pai, L.Y., Hayes, E.C., DaSilva, C.A., DiNinno, F., Rohrer, S.P., Schaeffer, J.M. and Hammond, M.L. (2004) Estrogen receptor ligands. Part 5: The SAR of dihydrobenzoxathiins containing modified basic side chains. Bioorganic & Medicinal Chemistry Letters, 14, 3747-3751. doi:10.1016/j.bmcl.2004.04.100
Dayan, G., Lupien, M., Auger, A., Anghel, S.I., Rocha, W., Croisetiere, S., Katzenellenbogen, J.A. and Mader, S. (2006) Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha. Molecular Pharmacology, 70, 579-588. doi:10.1124/mol.105.021931
MacGregor Schafer, J., Liu, H., Bentrem, D.J., Zapf, J.W. and Jordan, V.C. (2000) Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Research, 60, 5097-5105
Anghel, S.I., Perly, V., Melancon, G., Barsalou, A., Chagnon, S., Rosenauer, A., Miller, W.H. Jr. and Mader, S. (2000) Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens. Jounal of Biological Chememistry, 275, 20867-20872. doi:10.1074/jbc.M002098200